Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid

Journal of International Medical Research

Volumn 36, Issue 6, 2008, Pages 1342-1353

  Guo, F ^a   Chang, Chunkang K ^b   Fan, H H ^c   Nie, X X ^c   Ren, Y N ^c   Liu, Y Y ^c   Zhao, L H ^c  

^a SOOCHOW UNIVERSITY   (China)

^b Shanghai Number 6 Hospital   (China)

^c Shanghai Blood Centre   (China)

Author keywords

Anti cancer agents; Cancer; Cyclophosphamide; Exosomes; Poly i:C; Regulatory T cells; Toll like receptor; Tumour Immunology

Indexed keywords

CYCLOPHOSPHAMIDE; LIPOPOLYSACCHARIDE; POLYINOSINIC POLYCYTIDYLIC ACID; TUMOR ANTIGEN; TUMOR CELL VACCINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; INTERFERON INDUCING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CELL ACTIVATION; CELL ACTIVITY; CELL KILLING; CELL MATURATION; CELL PROLIFERATION; CELL SECRETION; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; EXOSOME; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA L 1210; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; SPLEEN CELL; SURVIVAL TIME; ANIMAL; CELL TRANSPLANTATION; DBA MOUSE; DRUG COMBINATION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; LONGEVITY; SECRETION; SPLEEN; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSPLANTATION; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; EXOSOMES; INTERFERON INDUCERS; LONGEVITY; MICE; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; POLY I-C; SPLEEN;

EID: 59649100584     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600623     Document Type: Article

References (25)

1. Johnstone RM, Adam M, Hammond JR, et al: Vesicle formation during reticulocyte maturation. J Biol Chem 1981; 262: 9412-9420.
2. Heijnen HF, Schiel AE, Fijnheer R, et al: Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules. Blood 1999; 94: 3791-3799.
3. Raposo G, Nijman HW, Stoorvogel W, et al: B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183: 1161-1172.
4. Blanchard N, Lankar D, Faure F, et al: TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζ complex. J Immunol 2002; 168: 3235-3241.
5. Raposo G, Tenza D, Mecheri S, et al: Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol Biol Cell 1997; 8: 2631-3645.
6. Van Niel G, Raposo G, Candalh C, et al: Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001; 121: 337-349.
7. Zitvogel L, Regnault A, Lozier A, et al: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4: 594-600.
8. Théry C, Duban L, Segura E, et al: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3: 1156-1162.
9. Kadowaki N, Ho S, Antonenko S, et al: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-869.
10. Segura E, Amigorena S, Théry C: Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis 2005; 35; 89-93.
11. + regulatory T cells inhibit protective immunity to filarial parasites in vivo. J Immunol 2007; 179: 4626-4634.
12. Loddenkemper C, Schernus M, Noutsias M, et al: In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 2006; 4: 52.
13. Taieb J, Chaput N, Schartz N, et al: Chemo-immunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006; 176: 2722-2729.
14. Chen Z, Dehm S, Bonham K, et al: DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 2001; 214: 60-71.
15. Lovrien R, Matulis D: Assays for total protein. Curr Protoc Microbiol 2005 Oct; Appendix 3: Appendix 3A.
16. Escudier B, Dorval T, Chaput N, et al: Vaccination of metastatic melanoma patients with antologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 2005; 3: 10.
17. Morse MA, Garst J, Osada T, et al: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3: 9.
18. André F, Chaput N, Schartz NE, et al: Exosomes as potent cell free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004; 172: 2126-2136.
19. Morelli AE, Larregina AT, Shufesky WI, et al: Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004; 104: 3257-3266.
20. Adikari SB, Pettersson A, Soderstrom M, et al: Interleukin-10-modulated immature dendritic cells control the proinflammatory environment in multiple sclerosis. Scand J Immunol 2004; 59: 600-606.
21. Cranmer LD, Hersh E: The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007; 25: 613-631.
22. Kadowaki N, Ho S, Antonenko S, et al: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-869.
23. Sutmuller R, Garritsen A, Adema GJ: Regulatory T cells and toll-like receptors: regulating the regulators. Ann Rheum Dis 2007; 66: 91-95.
24. Sakaguchi S, Yamaguchi T, Nomura T, et al: Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787.
25. Maki RG: Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 2006; 18: 363-368.